Keywords: fda, extends, levaquin, marketing, exclusivity, food, drug
FDA extends Levaquin marketing exclusivity
Article | 26 March 2007
The US Food and Drug Administration has granted Johnson & Johnson subsidiary Ortho-McNeil's Levaquin (levofloxacin) an additional six months of marketing ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- US Supreme Court says patent settlement can "sometimes" be illegal
- Negative US patent ruling for Novo Nordisk on Prandin
- Daiichi Sankyo files for Japanese approval of Prasugrel
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
